SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : CLTR COULTER PHARMACEUTICAL
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Vector1 who wrote (213)6/8/1999 1:25:00 PM
From: Biomaven  Read Replies (1) of 666
 
It might have helped if the release contained some more information. The 58% number free of disease progression is pretty meaningless without some information about time since treatment.

I know it's awfully hard to compare across trials, but it is worth looking at the Rituximab figures submitted for their NDA.

This shows 73/166 free of progression at the time of filing, and only 50/166 free four months later. These also seemed to be heavily pre-treated patients.

Statistics come from:

fda.gov

other info from:
fda.gov

Peter
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News